Novo Nordisk announced on September 29, 2026 that it has licensed an early-stage oral obesity drug candidate from the Chinese pharmaceutical company Hengrui Pharmaceutical, paying $300 million upfront with up to $2.6 billion more tied to development, regulatory, and commercial milestones.
What Novo Is Buying
The candidate, HRS-1596, is an oral, once-weekly small-molecule or peptide-based GLP-1/GIP receptor agonist that Hengrui describes as “Phase 1 ready.” That means it has not yet been tested in human clinical trials, so there is no efficacy or safety data in people to evaluate yet. Under the agreement, Novo obtains rights to develop and commercialize HRS-1596 in all territories outside mainland China, Taiwan, and Hong Kong, while Hengrui keeps rights to those markets.
Why Novo Is Doing This Deal
The licensing deal is part of a broader effort by Novo Nordisk to diversify and strengthen its obesity and diabetes pipeline as it faces intensifying competition from Eli Lilly's tirzepatide-based Zepbound and Mounjaro, which have been taking market share in both the injectable and oral GLP-1 categories. Novo's own oral semaglutide pill (Wegovy) has trailed Lilly's oral orforglipron (Foundayo) in recent earnings comparisons this site has covered. Novo also faces a longer-term concern about generic competition to its flagship semaglutide franchise beginning in the early 2030s, which has pushed the company to look further out in its pipeline for new mechanisms and formulations, including next-generation oral candidates like HRS-1596.
Hengrui's Growing Role as a Licensing Partner
Hengrui Pharmaceutical has become an unusually active out-licensor of drug candidates to Western pharmaceutical companies. According to reporting on the deal, this is the sixth licensing agreement Hengrui has signed with a U.S. or European drugmaker since early 2025, more than any other China-based biopharmaceutical company over that span. That pattern reflects a broader trend of large Western pharma companies turning to Chinese biotech firms for early-stage obesity and metabolic-disease candidates, a dynamic that has accelerated as the commercial GLP-1 market has grown.
How Early-Stage This Really Is
It's worth being clear-eyed about where HRS-1596 stands in drug development. A “Phase 1 ready” compound is, at best, several years and multiple clinical trial phases away from any possible FDA approval, and the large majority of drug candidates that enter Phase 1 testing never reach the market at all. The deal price reflects the size of the obesity drug market and Novo's strategic interest in the mechanism, not any demonstrated clinical result for this specific molecule. Large upfront and milestone-based licensing payments like this one are common in pharma dealmaking precisely because they let the buyer spread financial risk over years of trial results rather than paying full value for an unproven compound today; the bulk of that $2.6 billion figure would only be paid out if HRS-1596 clears a series of future clinical and regulatory hurdles.
The Bottom Line
This is a business and licensing story, not a clinical or regulatory milestone. No human trial data exists yet for HRS-1596, it is not close to an FDA submission, and nothing about currently available GLP-1 or GIP medications changes because of this announcement. Readers interested in oral GLP-1 options that are either already approved or in later-stage testing can see this site's coverage of orforglipron (Foundayo), oral semaglutide (Wegovy), and other candidates further along in development.